SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-317648
Filing Date
2021-11-03
Accepted
2021-11-03 07:10:05
Documents
14
Period of Report
2021-11-03
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d246302d8k.htm   iXBRL 8-K 25682
2 EX-99.1 d246302dex991.htm EX-99.1 103427
6 GRAPHIC g246302page1.jpg GRAPHIC 4319
  Complete submission text file 0001193125-21-317648.txt   274813

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA kpti-20211103.xsd EX-101.SCH 2885
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE kpti-20211103_lab.xml EX-101.LAB 18138
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kpti-20211103_pre.xml EX-101.PRE 11403
7 EXTRACTED XBRL INSTANCE DOCUMENT d246302d8k_htm.xml XML 3348
Mailing Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459
Business Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459 617-658-0600
Karyopharm Therapeutics Inc. (Filer) CIK: 0001503802 (see all company filings)

IRS No.: 263931704 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36167 | Film No.: 211373688
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences